Cargando…

Long-term anifrolumab safe in SLE

Detalles Bibliográficos
Autor principal:	McHugh, Jessica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	In Brief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809509/ https://www.ncbi.nlm.nih.gov/pubmed/36596927 http://dx.doi.org/10.1038/s41584-022-00902-4

Ejemplares similares

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
por: Casey, Kerry A, et al.
Publicado: (2018)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Publicado: (2018)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
por: Bruce, Ian N, et al.
Publicado: (2023)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Anifrolumab for Adolescent Discoid Lupus Erythematosus
por: Shaw, Katharina S., et al.
Publicado: (2023)

A case of Rowell syndrome with excellent improvement following anifrolumab
por: Shope, Chelsea, et al.
Publicado: (2022)

MIS-C is a risk factor for thrombotic events
por: McHugh, Jessica
Publicado: (2021)

Alopecia secondary to severe discoid lupus responding to anifrolumab
por: Han, Shannon, et al.
Publicado: (2023)

Safety, tolerability and pharmacokinetics of subcutaneous and intravenous anifrolumab in healthy volunteers
por: Tummala, Raj, et al.
Publicado: (2018)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
por: Chatham, W. Winn, et al.
Publicado: (2021)

A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
por: Kalunian, Kenneth C., et al.
Publicado: (2022)

Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2021)

Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment
por: Kirou, Kyriakos A., et al.
Publicado: (2022)

SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
por: Almquist, Joachim, et al.
Publicado: (2022)

Presentation of SLE in UK primary care using the Clinical Practice Research Datalink
por: Nightingale, Alison L, et al.
Publicado: (2017)

Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura
por: Boneparth, Alexis, et al.
Publicado: (2015)

Predictors of peripheral arterial disease in SLE change with patient’s age
por: Erdozain, Jose-Gabriel, et al.
Publicado: (2017)

LLDAS is an attainable treat-to-target goal in childhood-onset SLE
por: Wahadat, Mohamed Javad, et al.
Publicado: (2021)

Persistent expression of autoantibodies in SLE patients in remission
por: Yurasov, Sergey, et al.
Publicado: (2006)

Successful treatment of severe chronic cutaneous lupus with anifrolumab: A series of 6 cases
por: Kowalski, Eric H., et al.
Publicado: (2023)

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)

Evaluation of anifrolumab safety in systemic lupus erythematosus: A meta-analysis and systematic review
por: Liu, Zhihui, et al.
Publicado: (2022)

Cell-bound complement activation products associate with lupus severity in SLE
por: Arriens, Cristina, et al.
Publicado: (2020)

Jaccoud’s arthropathy in SLE: findings from a Latin American multiethnic population
por: Quintana, Rosana, et al.
Publicado: (2019)

Role of Anifrolumab in Refractory Cutaneous Manifestations of Lupus Erythematosus: A Case Series and Literature Review
por: Khan, Muhammad Atif, et al.
Publicado: (2023)

Viewpoint on anifrolumab in patients with systemic lupus erythematosus and a high unmet need in clinical practice
por: Tanaka, Yoshiya
Publicado: (2023)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
por: Chia, Yen Lin, et al.
Publicado: (2022)

Antibodies to FXa and thrombin in patients with SLE differentially regulate C3 and C5 cleavage
por: McDonnell, Thomas, et al.
Publicado: (2022)

Employing drug delivery strategies to create safe and effective pharmaceuticals for COVID‐19
por: McHugh, Kevin J.
Publicado: (2020)

Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy
por: Nunez, Daniel, et al.
Publicado: (2023)

Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks
por: Neupane, Binod, et al.
Publicado: (2023)

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
por: Jayne, David, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h467duvkmqpsafntjecbfee324